Cargando…

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer

In the absence of suitable molecular markers, non-small cell lung cancer (NSCLC) patients have to be treated with chemotherapy with poor results at advanced stages. Therefore, the activity of the anticancer marine drug fascaplysin was tested against primary NSCLC cell lines established from pleural...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plangger, Adelina, Rath, Barbara, Hochmair, Maximilian, Funovics, Martin, Neumayer, Christoph, Zeillinger, Robert, Hamilton, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993745/ https://www.ncbi.nlm.nih.gov/pubmed/34596822 http://dx.doi.org/10.1007/s10637-021-01181-8

Ejemplares similares

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
por: Plangger, Adelina, et al.
Publicado: (2021)

Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2018)

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines
por: Hochmair, Maximilian, et al.
Publicado: (2019)

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
por: Plangger, Adelina, et al.
Publicado: (2022)

Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2019)

Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
por: Rath, Barbara, et al.
Publicado: (2023)

FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular Modelling
por: Shafiq, Muhammad Imtiaz, et al.
Publicado: (2012)

Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard
Publicado: (2014)

Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
por: Rath, Barbara, et al.
Publicado: (2020)

Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs)
por: Plangger, Adelina, et al.
Publicado: (2021)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity
por: Ampofo, Emmanuel, et al.
Publicado: (2015)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
por: Abdullah, Nurul A, et al.
Publicado: (2021)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
por: Gelbert, Lawrence M., et al.
Publicado: (2014)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

Effects of metformin on human bone-derived mesenchymal stromal cell—breast cancer cell line interactions
por: Teufelsbauer, Maryana, et al.
Publicado: (2022)

Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients
por: Sajdik, Constantin, et al.
Publicado: (2022)

Comparison of the Inhibitory Binding Modes Between the Planar Fascaplysin and Its Nonplanar Tetrahydro-β-carboline Analogs in CDK4
por: Liang, Yan, et al.
Publicado: (2021)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017)

The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy
por: Hamilton, Gerhard, et al.
Publicado: (2021)

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production
por: Maria, Durvanei Augusto, et al.
Publicado: (2012)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase
por: Yu, Cheng-Han, et al.
Publicado: (2018)

Radiotherapy plus EGFR inhibitors: synergistic modalities
por: Bossi, Paolo, et al.
Publicado: (2017)

Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer
por: Hamilton, Gerhard, et al.
Publicado: (2015)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
por: Daemen, Anneleen, et al.
Publicado: (2012)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors
por: Alshaker, Heba, et al.
Publicado: (2018)

Administration of a TLR9 Inhibitor Attenuates the Development and Progression of Heart Failure in Mice
por: Ueda, Hiromichi, et al.
Publicado: (2019)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

Fascaplysin Sensitizes Anti-Cancer Effects of Drugs Targeting AKT and AMPK
por: Oh, Taek-In, et al.
Publicado: (2017)

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_obaijbjgj5evbdnduntlrbfns7